Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: A structured summary of a study protocol for an open-label randomized clinical trial

AbstractObjectiveGeneral: To assess the virucidal efficacy of povidone iodine (PVP-I) on COVID-19 virus located in the nasopharynxSpecific:i. To evaluate the efficacy of povidone iodine (PVP-I) to removeCOVID-19 virus located in the nasopharynxii. To assess the adverse events of PVP-ITrial designThis is a single-center, open-label randomized clinical trial with a 7-arm parallel-group design.ParticipantsThe study will be conducted at Dhaka Medical College Hospital, Dhaka, Bangladesh.Inclusion criteriaAll RT-PCR-confirmed COVID-19 cases aged between 15-90 years with symptoms for the past 4 days will be screened. Those who give informed consent, are willing to participate, and accept being randomized to any assigned group will also be considered for final inclusion.Exclusion criteriaPatients with known sensitivity to PVP-I aqueous antiseptic solution or any of its listed excipients or previously diagnosed thyroid disease or who had a history of chronic renal failure: stage ≥3 by estimated glomerular filtration rate (eGFR) Modification of Diet in Renal Disease (MDRD) or had acute renal failure (KDIGO ≥stage 2: creatinine ≥2 times from the baseline) or patients who required invasive or noninvasive ventilation or planned within the next 6 hours were considered for exclusion. Moreover, lactating or pregnant women will also be restricted to include here.Intervention and comparatorThis RCT consist of seven arms:Arm-1 (intervention group): will receive povidone iodine (PVP-I) nas...
Source: Trials - Category: Research Source Type: clinical trials